UNSPSC 51273016: Cyclomethycaine sulfate

This classification denotes an anesthetic agent with the molecular formula C22H33NO3.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7323N7T136. The term cyclomethycaine sulfate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule cyclomethycaine sulfate under HS 29333999 and SITC 51574. As of Q4 2014, CYCLOMETHYCAINE SULFATE remains US FDA's Preferred Term for this commodity. Cyclomethycaine sulfate bears US NLM identifiers UMLS ID C2699487 and NCI Concept Code C75089.

SMILES: CC1CCCCN1CCCOC(=O)C2CCC(CC2)OC3CCCCC3.CC1CCCCN1CCCOC(=O)C2CCC(CC2)OC3CCCCC3.OS(=O)(=O)O.

UNSPSC 51273016 Cyclomethycaine sulfate is a Commodity code that nominally designates a local anesthetic pharmaceutical ingredient, but recent state and local procurement activity tagged under this code shows little alignment with the specific chemical. The three most recent opportunities—a Seminole County naloxone and drug deactivation systems IFB, a Texas HHS Commission RFI on direct-to-manufacturer pharmacy programs, and a Minnesota multistate cooperative purchasing RFP for generic pharmaceuticals and OTC products—indicate that issuers are using the code to flag pharmaceutical procurement more broadly, including finished naloxone products, over-the-counter inventory, and pharmacy benefit program services rather than cyclomethycaine sulfate specifically. State and local health departments, multistate purchasing cooperatives, and health and human services commissions are the primary buyers; issuing bodies range from single counties to state health agencies to cooperative purchasing vehicles serving multiple jurisdictions.

The geographic spread includes Florida (Seminole County), Texas (state-level HHS Commission), and Minnesota (MMCAP, which serves participating states including Oregon). The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term. The Minnesota MMCAP RFP (S1070000015802, due March 26, 2026) established multi-award contracts for generic pharmaceuticals and OTC products across cooperating state and local facilities, requiring vendors to work through three authorized wholesalers and meet cGMP and Drug Supply Chain Security Act compliance. The Texas HHS Commission's RFI (HHS0017013, April 3, 2026) was exploratory, gathering vendor capabilities for a future direct-to-manufacturer pharmacy initiative rather than committing to procurement amounts or timelines. The code shows minimal recent activity narrowly aligned with cyclomethycaine sulfate itself; opportunities are tagged under the code but are pursuing broader pharmaceutical distribution and health agency supply rather than this specific anesthetic chemical.